Sutro Biopharma STRO Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$38.48M+17.7% | -$46.76M+17.8% | -$56.86M-394% | -$11.5M+84.9% | -$75.97M-4.9% | ||
| $1.28M-21.3% | $1.62M-14.5% | $1.9M0.0% | $1.9M0.0% | $1.9M+1.7% | ||
| $1.56M-5.6% | $1.66M+6.6% | $1.55M-70.5% | $5.26M-5.0% | $5.54M-6.4% | ||
| —— | $423.5K0.0% | $423.5K0.0% | $423.5K0.0% | $423.5K— | ||
| $8.51M— | $0+100% | -$4.08M+26.7% | -$5.56M-212% | $4.95M— | ||
| -$2.55M— | —— | —— | -$3.85M-104% | -$1.88M-146% | ||
| -$9.29M-766% | $1.39M-6.1% | $1.48M+607% | $210K+116% | -$1.35M-397% | ||
| $1M+120% | -$4.98M+37.4% | -$7.95M-24.1% | -$6.41M-58,173% | -$11K-100% | ||
| -$109K+1.8% | -$111K+29.3% | -$157K-16.3% | -$135K+19.6% | -$168K-7.7% | ||
| -$1.96M-1,250% | -$145K+97.6% | -$6.14M+89.5% | -$58.67M-1,129% | -$4.78M— | ||
| -$2.04M-2.8% | -$1.99M-2.8% | -$1.93M-7.1% | -$1.8M-2.7% | -$1.76M-2.7% | ||
| -$42.26M-59.9% | -$26.44M+30.8% | -$38.19M+14.6% | -$44.72M+34.1% | -$67.88M+5.4% | ||
| $0— | —— | $47K— | —— | $27K— | ||
| -$45.26M-342% | $18.7M-53.2% | $39.99M+1,450% | $2.58M+116% | -$16.26M-119% | ||
| —— | —— | —— | —— | —— | ||
| —— | $0— | $0— | $0— | $0— | ||
| $28K— | $0— | $0— | $0— | $0— | ||
| $160K+139% | $67K+168% | $25K-58.3% | $60K-66.7% | $180K+650% | ||
| $103.08M— | —— | $102K— | —— | $66K— | ||
| $15.55M+299% | -$7.8M— | $0+100% | -$42.2M+49.8% | -$84.08M-635% | ||
| -$15K-123% | $64K— | $0-100% | $4K-42.9% | $7K-99.7% | ||
| $445K-16.2% | $531K-29.7% | $755K-26.9% | $1.03M-7.4% | $1.12M-27.5% | ||
| —— | $423.5K0.0% | $423.5K0.0% | $423.5K0.0% | $423.5K— | ||
| $8.4M— | —— | —— | $1.56M-71.9% | $5.55M+846% | ||
| -$9.29M-766% | $1.39M-6.1% | $1.48M+607% | $210K+116% | -$1.35M-397% | ||
| -$2.04M-2.8% | -$1.99M-2.8% | -$1.93M-7.1% | -$1.8M-2.7% | -$1.76M-2.7% | ||
| $1M+120% | -$4.98M+37.4% | -$7.95M-24.1% | -$6.41M-58,173% | -$11K-100% | ||
| $9.47M-0.8% | $9.55M-1.6% | $9.7M0.0% | $9.7M+3.8% | $9.34M+7.5% | ||
| $1.2M-22.7% | $1.55M+3.5% | $1.5M+3.5% | $1.44M+3.4% | $1.4M+3.5% | ||
| -$109K+1.8% | -$111K+29.3% | -$157K-16.3% | -$135K+19.6% | -$168K-7.7% | ||
| $11K-94.0% | $184K-26.7% | $251K+192% | $86K-92.7% | $1.17M+9.9% | ||
| $103.13M— | $0— | $0— | $0— | $0-100% | ||
| $81K— | —— | $126K— | —— | $246K— | ||
| $0— | —— | $47K— | —— | $27K— | ||
| $435K— | —— | —— | —— | $0— | ||
| $911K+20.0% | $759K+17.5% | $646K-22.4% | $832K-29.3% | $1.18M+6.6% | ||
| -$1.96M-1,250% | -$145K+97.6% | -$6.14M+89.5% | -$58.67M-1,129% | -$4.78M— | ||
| -$2.04M-2.8% | -$1.99M-2.8% | -$1.93M-7.1% | -$1.8M-2.7% | -$1.76M-2.7% | ||
| $468K— | —— | —— | —— | $0— | ||
| -$15K-123% | $64K— | $0-100% | $4K-42.9% | $7K-99.7% | ||
| -$42.26M-60.2% | -$26.38M+31.0% | -$38.24M+14.5% | -$44.72M+34.1% | -$67.91M+5.3% | ||
| -$42.26M-60.2% | -$26.38M+31.0% | -$38.24M+14.5% | -$44.72M+34.1% | -$67.91M+5.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Sutro Biopharma generate?
- Sutro Biopharma (STRO) generated -$151.6M in operating cash flow over the trailing twelve months.
- What is Sutro Biopharma's free cash flow?
- After $627.0K of capital expenditures, Sutro Biopharma's free cash flow was -$151.6M over the trailing twelve months, up 25.9% year over year.
- Where does Sutro Biopharma's cash flow data come from?
- Every line is extracted from Sutro Biopharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
